CompletedPhase 2NCT02740972

Safety and Dose Finding Study of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD)

Studying Duchenne muscular dystrophy

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
NS Pharma, Inc.
Principal Investigator
Paula R. Clemens, MD
University of Pittsburgh
Intervention
NS-065/NCNP-01(drug)
Enrollment
16 enrolled
Eligibility
4-9 years · MALE
Timeline
20162018

Study locations (7)

Collaborators

Nippon Shinyaku Co., Ltd. · Cooperative International Neuromuscular Research Group · Therapeutic Research in Neuromuscular Disorders Solutions

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02740972 on ClinicalTrials.gov

Other trials for Duchenne muscular dystrophy

Additional recruiting or active studies for the same condition.

See all trials for Duchenne muscular dystrophy

← Back to all trials